According to Zacks, “Cutera Inc designs, develops, manufactures and markets the CoolGlide family of products for use in laser and other light-based aesthetic applications. The original CoolGlide CV provides permanent hair reduction on all skin types. The second generation CoolGlide Excel incorporated features that added the capability to treat a variety of vascular lesions, which include facial telangiectasia, spider and reticular leg veins. The CoolGlide Vantage added non-ablative skin therapy to the range of applications offered by the system. “
A number of other analysts also recently weighed in on CUTR. BidaskClub raised shares of Cutera from a “hold” rating to a “buy” rating in a research report on Friday, March 22nd. Stephens decreased their target price on shares of Cutera from $40.00 to $25.00 and set an “overweight” rating for the company in a research report on Thursday, February 21st. They noted that the move was a valuation call. Maxim Group reissued a “hold” rating on shares of Cutera in a research report on Monday, February 11th. ValuEngine raised shares of Cutera from a “buy” rating to a “strong-buy” rating in a research report on Monday, December 31st. Finally, TheStreet downgraded shares of Cutera from a “c” rating to a “d” rating in a research report on Thursday, February 21st. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $34.67.
Cutera (NASDAQ:CUTR) last released its earnings results on Wednesday, February 20th. The medical device company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.14). The firm had revenue of $45.47 million for the quarter, compared to analyst estimates of $44.29 million. Cutera had a negative net margin of 18.91% and a negative return on equity of 48.46%. The business’s revenue for the quarter was down 4.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.42 EPS. Equities research analysts forecast that Cutera will post -0.33 earnings per share for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in CUTR. Walthausen & Co. LLC acquired a new stake in shares of Cutera during the 4th quarter worth approximately $1,150,000. Gabelli Funds LLC grew its position in shares of Cutera by 19.9% during the 4th quarter. Gabelli Funds LLC now owns 610,407 shares of the medical device company’s stock worth $10,389,000 after buying an additional 101,207 shares during the period. BlackRock Inc. grew its position in shares of Cutera by 6.6% during the 3rd quarter. BlackRock Inc. now owns 2,024,978 shares of the medical device company’s stock worth $65,914,000 after buying an additional 126,213 shares during the period. Arizona State Retirement System grew its position in shares of Cutera by 6.7% during the 4th quarter. Arizona State Retirement System now owns 21,412 shares of the medical device company’s stock worth $364,000 after buying an additional 1,340 shares during the period. Finally, Chatham Capital Group Inc. grew its position in shares of Cutera by 14.1% during the 4th quarter. Chatham Capital Group Inc. now owns 32,092 shares of the medical device company’s stock worth $546,000 after buying an additional 3,967 shares during the period. 94.00% of the stock is owned by institutional investors and hedge funds.
Cutera Company Profile
Cutera, Inc, a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating.
Featured Article: Fundamental Analysis and Choosing Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.